SBIR Phase I: Mitigating the effects of isolation and absence of therapies through the delivery of cloud based digital treatments and remote patient monitoring

这个小型企业创新研究(SBIR)第一阶段项目的更广泛影响/商业潜力是改善100多万目前患有帕金森氏症(PD)的美国人的生活质量，同时减轻医疗保健系统日益增长的经济负担。门诊物理和职业治疗、言语治疗和心理健康是帕金森病治疗和管理的关键组成部分。使用这些疗法的早期干预和适当的对症处理对于最佳长期结果至关重要；治疗不足和罕见，特别是在新冠肺炎大流行期间，给帕金森氏症患者及其家人带来更重的负担，并给医疗保健系统带来更大的经济负担。通过拟议的家庭治疗平台提供远程治疗和监测表现可能表明症状减少或疾病进展放缓，从而有助于减少昂贵的不良医疗并发症，并提高PWP的生活质量。从定期的家庭和日常治疗中收集的数据可能会导致护理标准的提高，并帮助研究社区寻找治愈方法。一旦在PD的滩头市场被证明有效，这项技术就可以在阿尔茨海默氏症、痴呆症和老龄化的主流市场进行试验。这个小型企业创新研究(SBIR)第一阶段项目将为帕金森病(PD)患者开发一个自动治疗提供和远程患者监测平台的原型。这个自动化平台将通过监控实时功能以调整基于云的数字内容以优化身体表现、认知和对锻炼和认知任务的生理反应的家庭设备，促进远程治疗练习和社交活动，从而为帕金森氏症(PWP)患者提供日常治疗。这样的治疗系统应该具有与面对面治疗和治疗会议类似的疗效水平，使其能够参与到急需的治疗中，同时减轻PWP、他们的家人和医疗系统的负担。在每个疗程中收集的主观报告数据、生理反应数据和客观表现数据将汇总在一份报告中，提交给工务科、他们的家人和他们的照顾者或医疗保健提供者，以改善持续提供治疗、临床决策以及患者的健康和安全。这项拟议的技术将有助于减少隔离的影响，提供获得物理治疗和运动治疗的途径，并改善在整个新冠肺炎大流行危机期间及以后对患者的远程监控。该奖项反映了美国国家科学基金会的法定使命，并已通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to improve the quality of life for the more than 1 million Americans currently suffering from Parkinson’s Disease (PD) while reducing the growing economic burden on the healthcare system. Outpatient physical and occupational therapy, speech therapy, and mental health are key components in the treatment and management of PD. Early intervention and appropriate symptomatic management utilizing these therapies is essential for best long-term outcomes; Inadequate and infrequent treatment, especially during the COVID-19 pandemic, places a heavier burden on Person with Parkinson’s (PwP) and their families and a greater financial burden on the healthcare system. Delivering remote therapies and monitoring performance via the proposed in-home therapy platform may demonstrate a reduction in symptoms or slowing of disease progression, thereby helping to reduce costly, adverse medical complications and improving the PwP quality of life. Data collected from regular in-home, daily therapies may lead to improved standards of care and aid the research community in the search for a cure. Once proven effective in the beachhead market of PD, the technology could be trialed in the mainstream markets of Alzheimer’s, Dementia, and the aging population. This Small Business Innovation Research (SBIR) Phase I project will develop a prototype for an automated therapy delivery and remote patient monitoring platform for those suffering from Parkinson’s Disease (PD). This automated platform will provide access to daily therapies for the Person with Parkinson’s (PwP) by facilitating remote therapeutic exercise and social engagement via an in-home device that monitors real-time functionality to adapt cloud based digital content to optimize physical performance, cognition, and physiological response to exercise and cognitive tasks. Such a therapeutic system should have similar levels of efficacy as in-person therapy and treatment sessions, enabling participation in the much needed therapies while simultaneously reducing the burdens placed on the PwP, their families, and the healthcare system. The subjective report data, physiological response data, and objective performance data collected throughout each session will be summarized in a report for the PwP, their families, and their caregivers or healthcare providers to improve the continued delivery of treatment, clinical decision making, and health and safety of the patient. This proposed technology will help to reduce the effects of isolation, provide access to physical therapy and exercise treatments and improve the remote monitoring of patients throughout the COVID-19 pandemic crisis and beyond.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.